Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00133770 · ClinicalTrials.gov registry record · Phase 4

Intravenous (IV) Pantoprazole in Erosive Esophagitis

A Phase 4 study of Esophagitis, sponsored by Emory University.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT00133770 is a Phase 4 study of Esophagitis that has completed, run by Emory University. The registered enrollment target is 20 participants, below the 88-participant average among 5 other Esophagitis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00133770, a Phase 4 study of Esophagitis, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.

Conditions Studied

Interventions

  • DRUG pantoprazole

Study Locations (1)

Georgia

  • Emory University School of Medicine - Atlanta

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2004-07
Est. Completion 2007-03
Phase Phase 4

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT00133770

The ClinicalTrials.gov registry entry for NCT00133770 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 5 other Esophagitis trials with a reported enrollment target (77% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which pantoprazole is the first listed.

NCT00133770 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT00133770 about?

NCT00133770 is a clinical study titled "Intravenous (IV) Pantoprazole in Erosive Esophagitis". The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.

What is the current status of trial NCT00133770?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2004-07. Estimated completion is 2007-03.

What conditions does trial NCT00133770 study?

This clinical trial studies the following conditions: Esophagitis.

What interventions are being tested in trial NCT00133770?

The interventions under investigation include: pantoprazole (DRUG).

Who is sponsoring clinical trial NCT00133770?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00133770 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Esophagitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.